Satellos Bioscience Inc.
MSCL.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -4.53% | -33.57% | -37.61% | -74.63% | -96.19% |
| Total Depreciation and Amortization | 68.00% | 50.65% | 112.50% | 186.27% | -43.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -72.72% | 120.93% | 33.37% | -8.63% | 74.83% |
| Change in Net Operating Assets | -293.07% | -361.31% | -1,304.63% | -378.06% | 1,228.14% |
| Cash from Operations | -47.17% | -43.68% | -54.53% | -116.48% | -96.59% |
| Capital Expenditure | -27.66% | 75.41% | 79.17% | 70.15% | 62.99% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,203.98% | 207.30% | 146.79% | 141.13% | -- |
| Cash from Investing | -2,218.64% | 207.17% | 146.72% | 141.06% | 5,734.65% |
| Total Debt Issued | -- | -- | -- | -- | -93.76% |
| Total Debt Repaid | -- | -- | -- | -- | 90.06% |
| Issuance of Common Stock | 1,486.19% | 1,566.49% | 23.96% | 23.95% | -91.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 408.49% | 448.55% | -36.45% | -36.48% | -115.79% |
| Cash from Financing | 15,417.90% | 2,144.23% | 6.57% | 1.84% | -100.69% |
| Foreign Exchange rate Adjustments | 152.62% | 424.38% | 137.34% | 128.36% | -611.76% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 123.60% | 212.48% | 234.84% | 65.48% | -151.06% |